These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 3004325)

  • 1. Susceptibility of Campylobacter species to nalidixic acid, enoxacin, and other DNA gyrase inhibitors.
    Taylor DE; Ng LK; Lior H
    Antimicrob Agents Chemother; 1985 Nov; 28(5):708-10. PubMed ID: 3004325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of high-level quinolone resistance in Campylobacter jejuni.
    Gootz TD; Martin BA
    Antimicrob Agents Chemother; 1991 May; 35(5):840-5. PubMed ID: 1649570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incomplete cross-resistance of nalidixic and pipemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin, and norfloxacin.
    Traub WH
    Chemotherapy; 1985; 31(1):34-9. PubMed ID: 3156026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of Campylobacter hyointestinalis subsp. hyointestinalis to antimicrobial agents and characterization of quinolone-resistant strains.
    Laatu M; Rautelin H; Hänninen ML
    J Antimicrob Chemother; 2005 Feb; 55(2):182-7. PubMed ID: 15649999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.
    Chin NX; Neu HC
    Antimicrob Agents Chemother; 1983 Nov; 24(5):754-63. PubMed ID: 6229216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro activity of newer quinolones against aerobic bacteria.
    Auckenthaler R; Michéa-Hamzehpour M; Pechère JC
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibilities to 10 antimicrobial agents of 1,220 Campylobacter strains isolated from 1987 to 1993 from feces of pediatric patients.
    Reina J; Ros MJ; Serra A
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2917-20. PubMed ID: 7695284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Campylobacter laridis causing bacteremia in an immunosuppressed patient.
    Nachamkin I; Stowell C; Skalina D; Jones AM; Hoop RM; Smibert RM
    Ann Intern Med; 1984 Jul; 101(1):55-7. PubMed ID: 6375505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro activity of seven gyrase inhibitors of a group of heterocyclic carbonic acids against nonfermenting gram negative rods (nonfermenters)].
    Grimm H
    Arzneimittelforschung; 1985; 35(3):570-2. PubMed ID: 2986655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
    Bassey CM; Baltch AL; Smith RP
    J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams.
    Clarke AM; Zemcov SJ; Campbell ME
    J Antimicrob Chemother; 1985 Jan; 15(1):39-44. PubMed ID: 3156112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo antibacterial activity of AT-2266.
    Kouno K; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1983 Jul; 24(1):78-84. PubMed ID: 6226242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory evaluation of enoxacin: comparison with norfloxacin and nalidixic acid.
    Teoh-Chan CH; Cowlishaw A; Eley A; Slater G; Greenwood D
    J Antimicrob Chemother; 1985 Jan; 15(1):45-52. PubMed ID: 3156113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro activity of enoxacin against aminoglycoside-resistant gram-negative bacilli and other clinical isolates.
    Duncan IB; Skulnick M; Marshall PW
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():1-6. PubMed ID: 6438046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nalidixic acid analogues and Shigella.
    Bannatyne RM; Toma S; Cheung R
    Lancet; 1984 Jul; 2(8395):172-3. PubMed ID: 6146075
    [No Abstract]   [Full Text] [Related]  

  • 16. Intraphagocytic bactericidal activity of bacterial DNA gyrase inhibitors against Serratia marcescens.
    Traub WH
    Chemotherapy; 1984; 30(6):379-86. PubMed ID: 6097410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
    Guimaraes MA; Noone P
    J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound.
    Chartrand SA; Scribner RK; Weber AH; Welch DF; Marks MI
    Antimicrob Agents Chemother; 1983 May; 23(5):658-63. PubMed ID: 6223577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The comparative activity of pefloxacin, enoxacin, ciprofloxacin and 13 other antimicrobial agents against enteropathogenic microorganisms.
    Vanhoof R; Hubrechts JM; Roebben E; Nyssen HJ; Nulens E; Leger J; De Schepper N
    Infection; 1986; 14(6):294-8. PubMed ID: 3546145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of enoxacin compared with norfloxacin and amikacin.
    van der Auwera P; de Moor G; Lacroix G; Mambour A; Rossion N; Schuyteneer F
    Eur J Clin Microbiol; 1985 Feb; 4(1):55-8. PubMed ID: 3157568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.